FDA Clearance Tracker · P170024
Surpass Streamline Flow Diverter
Last checked: Nov 19, 2026Latest source record: Jul 13, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jul 13, 2018
Approved
Time to decision
347 days
Received Jul 31, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P170024
- Device name
- Surpass Streamline Flow Diverter
- Applicant
- Stryker Neurovascular
- Applicant location
- Fremont, CA
- Received
- Jul 31, 2017
- Decided
- Jul 13, 2018
- Decision
- Approved
- Supplements
- 26 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Intracranial aneurysm flow diverter (OUT)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for The Surpass Streamline Flow Diverter. The Surpass Streamline Flow Diverter is indicated for use in the endovascular treatment of patients (18 years of age and older) with unruptured large or giant saccular wide-neck (neck width >= 4 mm or dome-to-neck ratio < 2) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter >= 2.5 mm and <= 5.3 mm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OUT. The earliest in FDA's data is P100018, decided Apr 6, 2011.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Stryker Neurovascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261649 · Decided Oct 9, 2026 · 143 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
K261889 · Decided Jul 1, 2026 · 26 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
K253032 · Decided Feb 11, 2026 · 142 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.